GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » EBITDA per Share

Pressure BioSciences (Pressure BioSciences) EBITDA per Share : $-0.33 (TTM As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences EBITDA per Share?

Pressure BioSciences's EBITDA per Share for the three months ended in Sep. 2023 was $-0.06. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.33.

During the past 3 years, the average EBITDA per Share Growth Rate was 46.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Pressure BioSciences's EBITDA per Share or its related term are showing as below:

PBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -190.2   Med: 18.8   Max: 46.5
Current: 46.5

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Pressure BioSciences was 46.50% per year. The lowest was -190.20% per year. And the median was 18.80% per year.

PBIO's 3-Year EBITDA Growth Rate is ranked better than
90.99% of 710 companies
in the Medical Devices & Instruments industry
Industry Median: 7.9 vs PBIO: 46.50

Pressure BioSciences's EBITDA for the three months ended in Sep. 2023 was $-1.26 Mil.

During the past 3 years, the average EBITDA Growth Rate was 5.20% per year. During the past 5 years, the average EBITDA Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Pressure BioSciences was 39.10% per year. The lowest was -125.40% per year. And the median was -3.90% per year.


Pressure BioSciences EBITDA per Share Historical Data

The historical data trend for Pressure BioSciences's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences EBITDA per Share Chart

Pressure BioSciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.55 -3.26 -2.28 -0.84 -0.50

Pressure BioSciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.03 -0.19 -0.05 -0.06

Pressure BioSciences EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Pressure BioSciences's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA per Share(A: Dec. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-5.518/11.058
=-0.50

Pressure BioSciences's EBITDA per Share for the quarter that ended in Sep. 2023 is calculated as

EBITDA per Share(Q: Sep. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.263/21.717
=-0.06

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences  (OTCPK:PBIO) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Pressure BioSciences EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences (Pressure BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067

Pressure BioSciences (Pressure BioSciences) Headlines

From GuruFocus